Plexium: Abbvie and Plexium Enter Into Multi-Target Strategic Collaboration To Develop and Commercialize Targeted Protein Degradation Therapies for Neurological Conditions
Plexium, Inc. (Plexium) and AbbVie (NYSE: ABBV) have entered into an exclusive strategic collaboration to develop and commercialize novel Targeted Protein Degradation (TPD) therapeutics for neurological conditions.
Read full article »
President & CEO
Michael Martin
Plexium is a California-based biotechnology company that develops a platform that provides targeted protein degradation therapies for the treatment of cancer.
Read more